Clinical study of neoadjuvant chemotherapy before radiotherapy for locally advanced cervical cancer

doi:10.13406/j.cnki.cyxb.002831

您当前的位置：

首页 >

文章列表页 >

Clinical study of neoadjuvant chemotherapy before radiotherapy for locally advanced cervical cancer

更新时间：2024-01-09

- Clinical study of neoadjuvant chemotherapy before radiotherapy for locally advanced cervical cancer
- Journal of Chongqing Medical University Vol. 46, Issue 6, Pages: 681-684(2021)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.002831
  CLC： R737.33
- Published：2021，
扫描看全文
Clinical study of neoadjuvant chemotherapy before radiotherapy for locally advanced cervical cancer. [J]. Journal of Chongqing Medical University 46(6):681-684(2021)
DOI：

Clinical study of neoadjuvant chemotherapy before radiotherapy for locally advanced cervical cancer. [J]. Journal of Chongqing Medical University 46(6):681-684(2021) DOI： 10.13406/j.cnki.cyxb.002831.

摘要

目的：探讨放疗前行新辅助化疗（neoadjuvant chemotherapy，NACT）的局部晚期宫颈癌（locally advanced cervical cancer，LACC）患者治疗情况及临床疗效。方法：纳入2013年1月至2017年12月重庆大学附属肿瘤医院收治的IB2~IVA期宫颈鳞癌患者150例，均在放疗前行NACT，评估患者的治疗及骨髓抑制发生情况，分析1年和3年总生存率（overall survival，OS）、无进展生存率（progression-free survival，PFS）。结果： 36例（24%）放疗期间未能同步化疗，而同步化疗的患者中有48例（42.11%）未足疗程完成；55例（36.67%）放疗时程>56 d；71例（47.33%）发生了Ⅲ级以上骨髓抑制。近期客观缓解率（objective response rate，ORR）为84.66%，其中完全缓解率（complete response，CR）仅25.33%。112例（74.67%）给予不同程度的后续辅助治疗。1年和3年OS、PFS分别为90.0%和66.7%、66.7%和46.7%。结论： LACC患者放疗前行NACT，降低了放疗的耐受性，延长了放疗时程，影响了同步化疗的实施，未延长患者的OS、PFS，并未改善LACC患者的预后。

Abstract

Objective: To investigate the therapeutic status and clinical curative effects of patients with locally advanced cervical cancer (LACC) who underwent neoadjuvant chemotherapy (NACT) before radiotherapy. Methods: Totally 150 cases of LACC (IB2-IVA) admitted to Chongqing University Cancer Hospital from January 2013 to December 2017 were collected in this study. All patients underwent NACT before radiotherapy. The therapeutic status and myelosuppression were evaluated

and the overall survival (OS) and progression-free survival (PFS) of 1 year and 3 years were analyzed. Results: The concurrent chemotherapy for 36 cases (24%) were not administered during radiotherapy

and 48 cases (42.11%) did not complete the full course of chemotherapy among patients receiving concurrent chemotherapy. The duration of radiotherapy for 55 cases (36.67%) were more than 56 days. The GradeⅢor higher myelosuppression were occurred in 71 patients (47.33%). The recent objective response rate (ORR) was 84.66%

but the complete response (CR) was only 25.33%. A total of 112 cases (74.67%) were given various forms of follow-up adjuvant therapy. The OS and PFS of 1 year and 3 years were 90.0% and 66.7%

and 66.7% and 46.7%

respectively. Conclusion: The NACT before radiotherapy for LACC patients reduces the tolerance to radiation therapy

prolongs the duration of radiotherapy

affects the implementation of concurrent chemotherapy

and the prognosis of LACC patients is not improved because the OS and PFS are not prolonged.

关键词

局部晚期宫颈癌新辅助化疗同步化疗

Keywords

locally advanced cervical cancerneoadjuvant chemotherapyconcurrent chemotherapy

references

Views

136

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pathomics signature based on machine learning can predict the response to neoadjuvant chemotherapy in breast cancer patients

Study on radiotherapy plus neoadjuvant chemotherapy for patients with upper esophageal carcinoma

Prediction of chemosensitivity to combination neoadjuvant chemotherapy with carboplatin and 5-Fu for the patients with oral squamous cell carcinoma

Relationship between expression of p53、cerbB-2 and the effect of neoadjuvant chemotherapy using taxinol and epirubicin in breast cancer

Related Author

Zou Dongling

Guo Mingfang

Zhang Jieqiu

Wu Qi

Wang Jianmei

Yao Xiaopeng

陈晓品

et al

Related Institution

Department of Medical Engineering Technology，School of Medical Information and Engineering，Southwest Medical University

Department of Pathology，The Affiliated Hospital of Southwest Medical University

Department of Epidemiology and Health Statistics， School of Public Health，Southwest Medical University

重庆医科大学附属第一医院肿瘤科

⁰